glioblastoma

(redirected from glioblastoma multiforme)
Also found in: Thesaurus, Medical, Acronyms, Wikipedia.

gli·o·blas·to·ma

 (glē′ō-blă-stō′mə, glī′-)
n. pl. gli·o·blas·to·mas or gli·o·blas·to·ma·ta (-mə-tə)
A malignant tumor of the central nervous system, usually occurring in the cerebrum of adults.

glioblastoma

(ˌɡlaɪəʊblæsˈtəʊmə; ˌɡliːəʊ-)
adj
(Pathology) med a malignant tumour of the central nervous system
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.glioblastoma - a fast-growing malignant brain tumor composed of spongioblasts; nearly always fatal
brain tumor, brain tumour - a tumor in the brain
Translations
glioblastoma

glioblastoma

n. glioblastoma, tipo de tumor cerebral.

glioblastoma

n glioblastoma m; glioblastoma multiforme glioblastoma multiforme
References in periodicals archive ?
En otro estudio, utilizando 129 muestras de pacientes operados por glioblastoma multiforme, se estudio la expresion de PTEN y su relacion con sobrevida, encontrandose diferencias estadisticamente significativas a favor de los pacientes sin perdida de PTEN, con un periodo de sobrevida de 166 dias vs 437 dias (Backlund et al., 2003).
The "Glioblastoma Multiforme Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.
"Recurrent glioblastoma multiforme is an aggressive and life-threatening cancer of the central nervous system for which there are few treatment options and no cure," said Laurence Cooper, M.D., Ph.D., chief executive officer of Ziopharm.
Her diagnosis of glioblastoma multiforme, often referred to as grade IV astrocytoma, is one of less than 200 documented cases in the past 40 years in which the tumor is in her spine rather than the brain.
Keywords: Glioblastoma multiforme, tumour markers, MGMT methylation.
Patients diagnosed with glioblastoma multiforme are expected to live about 15 months after diagnosis.
Glioblastoma multiforme (GBM) is a common primary central nervous system (CNS) neoplasm in adults with a very aggressive natural history and grim prognosis [1, 2].
Nghiemphu et al., "Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme," Journal of Clinical Oncology, vol.
Maryland Heights, MO, October 27, 2016 --(PR.com)-- Glioblastoma Multiforme Drugs Market 2013-2020 report estimates the global Glioblastoma multiforme drugs market to reach nearly USD 785 Million in 2020, at a CAGR of 13.4% from 2016 to 2020 - iHealthcareAnalyst, Inc.